USA Financial Formulas Buys New Position in Illumina, Inc. $ILMN

USA Financial Formulas bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,127 shares of the life sciences company’s stock, valued at approximately $582,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Fiduciary Financial Advisors acquired a new position in Illumina during the second quarter worth $26,000. MCF Advisors LLC lifted its holdings in Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina in the second quarter valued at about $32,000. Rakuten Securities Inc. acquired a new stake in shares of Illumina in the second quarter valued at about $33,000. Finally, WealthCollab LLC grew its position in shares of Illumina by 51.5% in the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 103 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares in the company, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on ILMN. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Barclays raised their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research note on Wednesday, October 7th. Leerink Partners lifted their price objective on Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $225.94.

Illumina Price Performance

Illumina stock opened at $262.54 on Friday. Illumina, Inc. has a 52-week low of $94.00 and a 52-week high of $309.35. The firm has a market capitalization of $39.64 billion, a price-to-earnings ratio of 48.98, a PEG ratio of 3.72 and a beta of 1.41. The company has a fifty day simple moving average of $234.53 and a 200-day simple moving average of $186.01. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.